Multiple Sclerosis News

WEST PALM BEACH, Fla. — No correlation was found between depression and self-report of disability in a small group of patients with multiple sclerosis, according to a poster from ACTRIMS 2024.

WEST PALM BEACH, Fla. — In two separate cohorts of individuals with multiple sclerosis and memory issues, better sleep was linked to improved verbal memory, according to a poster at ACTRIMS 2024.

WEST PALM BEACH, Fla. — For patients with multiple sclerosis living in underserved areas, increasing access to health care professionals and removing barriers of access to technology are urgent needs, according to a speaker at ACTRIMS 2024.

The FDA has approved a supplemental new drug application for an Acthar Gel injector for the treatment of several chronic and acute inflammatory and autoimmune conditions, according to the manufacturer.

WEST PALM BEACH, Fla. — Application of a machine learning model to databases of patients with multiple sclerosis expanded understanding of disease progression, according to a poster at ACTRIMS 2024.

WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.

WEST PALM BEACH, Fla. — Oral administration of vidofludimus calcium reduced fatigue over 14 days compared with placebo and may have a long-term positive effect in multiple sclerosis, according to a poster presented at ACTRIMS 2024.

For individuals with pediatric-onset multiple sclerosis, treatment with commonly known highly effective therapies was associated with reduced relapse risk and optimal outcome within the first 2 years, researchers wrote in JAMA Neurology.

An Indianapolis-area biopharmaceutical company announced it has raised $30 million in Series B financing to advance investigational tyrosine kinase 2 inhibitors for multiple sclerosis as well as dermatologic conditions.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.